 |
| 27-Jan-12 | Reiterated |
Canaccord Genuity |
Buy |
$17 |
|
| 20-Sep-11 | Reiterated |
Wedbush |
Outperform |
$29 → $24 |
|
| 20-Sep-11 | Reiterated |
Canaccord Genuity |
Buy |
$27 → $15 |
|
| 15-Apr-11 | Initiated |
UBS |
Neutral |
$17 |
|
| 26-Jan-11 | Reiterated |
Rodman & Renshaw |
Mkt Outperform |
$32 → $22 |
|
| 02-Nov-10 | Reiterated |
Oppenheimer |
Outperform |
$34 → $32 |
|
| 26-Aug-10 | Reiterated |
Rodman & Renshaw |
Mkt Outperform |
$24 → $32 |
|
| 26-Jul-10 | Reiterated |
Wedbush |
Outperform |
$20 → $29 |
|
| 13-May-10 | Reiterated |
Oppenheimer |
Outperform |
$17 → $19 |
|
| 19-Nov-09 | Upgrade |
Oppenheimer |
Perform → Outperform |
$15 |
|
| 18-Nov-09 | Initiated |
Canaccord Adams |
Buy |
|
|
| 18-Sep-09 | Initiated |
Deutsche Securities |
Buy |
$15 |
|
| 19-May-09 | Initiated |
Wedbush Morgan |
Buy |
$15 |
|
| 13-Feb-09 | Upgrade |
Stanford Research |
Hold → Buy |
$17 |
|
| 05-Jan-09 | Initiated |
Leerink Swann |
Outperform |
$16 |
|
| 08-May-08 | Downgrade |
Bear Stearns |
Outperform → Peer Perform |
|
|
| 29-Apr-08 | Upgrade |
Rodman & Renshaw |
Mkt Perform → Mkt Outperform |
$30 |
|
| 21-Feb-08 | Reiterated |
Deutsche Securities |
Hold |
$6 → $8 |
|
| 07-Nov-07 | Downgrade |
Rodman & Renshaw |
Mkt Outperform → Mkt Perform |
|
|
| 07-Nov-07 | Downgrade |
Deutsche Securities |
Buy → Hold |
|
|
|
|
| 17-May-13 01:04PM | MOMENTA PHARMACEUTICALS INC Financials EDGAR Online Financials |
| 16-May-13 12:17AM | Momenta Pharmaceuticals Management Presents at Bank of America Merrill Lynch Health Care Conference (Transcript) at Seeking Alpha |
| 13-May-13 04:36PM | Momenta Pharmaceuticals (MNTA) Shares Cross Above 200 DMA at TheStreet |
| 10-May-13 05:03AM | MOMENTA PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report EDGAR Online +7.49% |
| 09-May-13 04:30PM | Momenta Pharmaceuticals to Webcast Presentations at Two Upcoming Investor Conferences GlobeNewswire |
| 02-May-13 12:00PM | 5 Names Seeing Bullish Options Flow at TheStreet |
| 11:25AM | Big Generic Drug Players See Best Topline Growth Rates in Emerging Markets: Expert Analyst David Amsellem Discusses the Generic Drug Space with The Wall Street Transcript Wall Street Transcript |
| 30-Apr-13 02:50PM | Momenta Pharmaceuticals' CEO Discusses Q1 2013 Results - Earnings Call Transcript at Seeking Alpha |
| 12:39PM | Oversold Conditions For Momenta Pharmaceuticals (MNTA) at TheStreet |
| 11:04AM | Momenta Pharmaceuticals Earnings: Heres Why Shares are Down Now at Wall St. Cheat Sheet |
| 08:00AM | Momenta Pharmaceuticals Reports First Quarter 2013 Financial Results GlobeNewswire |
| 07:07AM | Q1 2013 Momenta Pharmaceuticals, Inc. Earnings Release - Before Market Open CCBN |
| 01:41AM | MOMENTA PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements a EDGAR Online |
| 29-Apr-13 01:07PM | 3 Biotech Companies for Young Investors at Motley Fool |
| 22-Apr-13 12:30PM | Momenta Pharmaceuticals Breaks Above 200-Day Moving Average - Bullish For MNTA at TheStreet |
| 09-Apr-13 04:15PM | Momenta Pharmaceuticals Announces Date of First Quarter 2013 Financial Results Conference Call and Webcast GlobeNewswire |
| 27-Mar-13 08:40AM | Stocks With Upcoming Legal Catalysts at Seeking Alpha |
| 14-Mar-13 11:34AM | Momenta Pharmaceuticals Management Presents at Barclays Healthcare Conference - Transcript at Seeking Alpha |
| 13-Mar-13 06:56AM | New Drugs Tempt Lupin to Spend Up to $1 Billion: Corporate India at Bloomberg |
| 12-Mar-13 02:32PM | New Drugs Tempt Lupin to Spend Up to $1 Billion: Corporate India at Bloomberg |
| 10-Mar-13 01:34AM | Teva Advances as Savings May Offset Competition: Tel Aviv Mover at Bloomberg |
| 07-Mar-13 09:40AM | Teva Advances as Savings May Offset Competition: Tel Aviv Mover at Bloomberg |
| 05:15AM | Teva Advances as Savings May Offset Competition: Tel Aviv Mover at Bloomberg |
| 04:44AM | Teva Advances as Savings May Offset Competition: Tel Aviv Mover at Bloomberg |
| 06-Mar-13 01:04PM | MOMENTA PHARMACEUTICALS INC Financials EDGAR Online Financials |
| 28-Feb-13 04:29PM | MOMENTA PHARMACEUTICALS INC Files SEC form 10-K, Annual Report EDGAR Online |
| 26-Feb-13 08:47AM | Momenta taps into emerging market of biosimilars at bizjournals.com |
| 25-Feb-13 04:30PM | Momenta Pharmaceuticals to Webcast Presentations at Two Upcoming Investor Conferences GlobeNewswire |
| 22-Feb-13 01:15PM | MOMENTA PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and E EDGAR Online |
| 19-Feb-13 03:58PM | Loss at MNTA Narrower than Expected Zacks |
| 18-Feb-13 07:51PM | New Star Analyst Rankings for Momenta Pharmaceuticals, Inc. StarMine |
| 15-Feb-13 02:20PM | Momenta Pharmaceuticals CEO Discusses Q4 2012 Results - Earnings Call Transcript at Seeking Alpha |
| 02:12PM | Momenta Pharmaceuticals sticks to guidance despite revenue plunge at bizjournals.com |
| 10:57AM | Momenta Pharmaceuticals Earnings: Heres Why Investors are Happy Now at Wall St. Cheat Sheet |
| 09:34AM | MOMENTA PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements a EDGAR Online |
| 08:08AM | Momenta Pharma stills sees 2013 operating cash use about $90M theflyonthewall.com |
| 08:02AM | InPlay: Momenta Pharma beats by $0.07, beats on revs Briefing.com |
| 08:00AM | Momenta Pharmaceuticals Reports Fourth Quarter and Year End 2012 Financial Results GlobeNewswire |
| 07:07AM | Q4 2012 Momenta Pharmaceuticals, Inc. Earnings Release - Before Market Open CCBN |
| 07-Feb-13 11:24AM | MOMENTA PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement EDGAR Online |
| 09:00AM | Momenta Pharmaceuticals to Webcast Presentations at Two Upcoming Investor Conferences GlobeNewswire |
| 04-Feb-13 11:00PM | 3 Things to Watch at Momenta Pharmaceuticals at Motley Fool |
| 28-Jan-13 09:24PM | Biotech Firms, Billions at Risk, Lobby States to Limit Generics at New York Times |
| 09:24PM | Battle in States on Generic Copies of Biotech Drugs at New York Times |
| 09:24PM | Battle in States on Generic Copies of Biotech Drugs at New York Times |
| 24-Jan-13 08:30AM | Momenta Pharmaceuticals Announces Date of Fourth Quarter and Year End 2012 Financial Results Conference Call and Webcast GlobeNewswire |
| 09-Jan-13 02:02PM | Biotech's a Buy, but Hold Off on HMOs: Fund Manager at CNBC |
| 02-Jan-13 11:26AM | 2013 Should Be Interesting for Multiple Sclerosis Drugs at Motley Fool |
| 06-Dec-12 02:53PM | The Worst of 2012: Momenta Pharmaceuticals at Motley Fool |
| 04-Dec-12 07:26PM | Momenta Pharmaceuticals' Management Presents at Deutsche Bank 2012 dbAccess BioFEST Conference (Transcript) at Seeking Alpha |
| 03-Dec-12 04:09AM | Momenta Pharmaceuticals Inc. Stock Downgraded (MNTA) at TheStreet |
| 30-Nov-12 06:33PM | Teva Guides for Disappointment at Motley Fool |
| 27-Nov-12 04:30PM | Momenta Pharmaceuticals to Present at the Deutsche Bank 2012 dbAccess BioFEST GlobeNewswire |
| 24-Nov-12 03:58PM | Hatching Ideas, and Companies, by the Dozens at M.I.T. at New York Times |
| 20-Nov-12 12:41PM | InPlay: Momenta Pharma: U.S. Court of Appeals denied Momenta Pharmaceuticals petition for rehearing en banc in "safe-harbor" case Briefing.com |
| 12:41PM | U.S. Court of Appeals Denied Momenta Pharmaceuticals Petition for Rehearing En Banc in "Safe-Harbor" Case GlobeNewswire |
| 15-Nov-12 05:55PM | Momenta Pharmaceuticals' Management Presents at Credit Suisse 2012 Healthcare Conference (Transcript) at Seeking Alpha |
| 14-Nov-12 06:59PM | Momenta Pharmaceuticals' Management Presents at Lazard Capital Markets 9th Annual Healthcare Conference (Transcript) at Seeking Alpha |
| 01:04PM | MOMENTA PHARMACEUTICALS INC Financials EDGAR Online Financials |
| 09-Nov-12 12:55PM | [$$] Momenta Pharmaceuticals, Apple: Money Flow Leaders (MNTA, AAPL) at The Wall Street Journal |
| 12:55PM | Visterra lands $13M from Gates Foundation, others at bizjournals.com |
| 08-Nov-12 04:30PM | Momenta Pharmaceuticals to Webcast Presentations at Two Upcoming Investor Conferences GlobeNewswire |
| 12:47PM | MOMENTA PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report EDGAR Online |
| 09:33AM | New Star Analyst Rankings for Momenta Pharmaceuticals, Inc. StarMine |
| 08:02AM | Momenta Reveals Projections and 2 Stocks Dipping to 52-Week Lows at Wall St. Cheat Sheet |
| 07-Nov-12 06:48PM | Why Momenta Stalled at Motley Fool -8.34% |
| 04:02PM | Momenta Pharmaceutical's CEO Discusses Q3 2012 Results - Earnings Call Transcript at Seeking Alpha |
| 09:11AM | MOMENTA PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements a EDGAR Online |
| 08:16AM | Momenta Pharma CEO: Q3 royalty rev from enoxaparin sodium injection disappoints theflyonthewall.com |
| 08:04AM | InPlay: Momenta Pharma misses by $0.24, misses on revs Briefing.com |
| 08:00AM | Momenta Pharmaceuticals Reports Third Quarter 2012 Financial Results GlobeNewswire |
| 07:07AM | Q3 2012 Momenta Pharmaceuticals, Inc. Earnings Release - Before Market Open CCBN |
| 01-Nov-12 06:36PM | Has Baxter International Become the Perfect Stock? at Motley Fool |
| 19-Oct-12 09:00AM | A Refreshing Outlook - Consensus Reports on Keryx Biopharmaceuticals, Inc. and Momenta Pharmaceuticals, Inc. Marketwire |
| 18-Oct-12 04:48PM | Momenta Pharmaceuticals Announces Date of Third Quarter 2012 Financial Results Conference Call GlobeNewswire |
| 05-Oct-12 11:34AM | Has Teva Pharmaceutical Become the Perfect Stock? at Motley Fool |
| 16-Sep-12 10:00AM | 3 Things to Watch With Teva Pharmaceutical at Motley Fool |
| 14-Sep-12 11:55AM | 4 Low-Debt Healthcare Stocks Raking In Profits at Seeking Alpha |
| 12-Sep-12 11:59AM | Momenta Pharmaceuticals' CEO to Present at Morgan Stanley Healthcare Conference (Transcript) at Seeking Alpha |
| 31-Aug-12 02:26PM | A Good Start on the Biosimilar Front at Motley Fool |
| 30-Aug-12 05:00PM | Momenta Pharmaceuticals to Webcast Presentations at Two Upcoming Investor Conferences GlobeNewswire |
| 14-Aug-12 01:04PM | MOMENTA PHARMACEUTICALS INC Financials EDGAR Online Financials |
| 10-Aug-12 04:06AM | 7 Profitable Healthcare Stocks That Analysts Love at Seeking Alpha |
| 08-Aug-12 04:01PM | Momenta to Present at the Canaccord Genuity 32nd Annual Growth Conference GlobeNewswire |
| 09:08AM | MOMENTA PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report EDGAR Online |
| 06-Aug-12 11:32AM | Second quarter results strongest in five years, report said at bizjournals.com |
| 07:00AM | Momenta, Samsung, Zynga, Netflix: Intellectual Property at Bloomberg |
| 12:00AM | Momenta, Samsung, Zynga, Netflix: Intellectual Property at Bloomberg |
| 04-Aug-12 02:41AM | 4 Small-Cap Biotech Stocks Generating Profits With Buy Ratings at Seeking Alpha |
| 03-Aug-12 05:29PM | Momenta Loses in Appeals Court Over Watsons Lovenox Copy at Bloomberg |
| 04:58PM | InPlay: Momenta Pharma acknowledges Federal Circuit opinion supporting order issued January 26, 2012 in ongoing suit against Amphastar Pharmaceuticals and Watson Pharmaceuticals (WPI) Briefing.com |
| 04:56PM | Momenta Pharmaceuticals Acknowledges Federal Circuit Opinion Supporting Order Issued January 26, 2012 in Ongoing Suit Against Amphastar Pharmaceuticals and Watson Pharmaceuticals GlobeNewswire |
| 02:51PM | Momenta Loses in Appeals Court Over Watsons Lovenox Copy at Bloomberg |
| 12:32PM | Biggest Healthcare Sector Movers, Including ALXN at Investopedia |
| 11:52AM | Momenta Loses in Appeals Court Over Watsons Lovenox Copy at Bloomberg |
| 10:58AM | New Star Analyst Rankings for Momenta Pharmaceuticals, Inc. StarMine |
| 02-Aug-12 05:03PM | Momentas' CEO Discusses Q2 2012 Results - Earnings Call Transcript at Seeking Alpha |
| 10:28AM | Equity Briefing: Earnings Results for August 2nd: GM, GNRC, GTIV, GTLS, GWR, HEES, HGG, HOS, HSIC, IIVI, INCY Thomson Reuters ONE |
| 09:15AM | MOMENTA PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements a EDGAR Online |
| 08:04AM | InPlay: Momenta Pharma misses by $0.03, beats on revs Briefing.com |
|
|
| Momenta Pharmaceuticals, Inc., a biotechnology company, engages in the structural characterization, process engineering, and biologic systems analysis of complex molecules. Its complex molecules include polysaccharides, polypeptides, and proteins and antibodies. The company's complex generics programs comprise Enoxaparin sodium injection, a generic version of Lovenox that is used for the prevention and treatment of deep vein thrombosis, and to support the treatment of acute coronary syndromes; and M356, a generic version of Copaxone, which is a glatiramer acetate injection indicated for the reduction of the frequency of relapses in patients with relapsing-remitting multiple sclerosis. Its biosimilars programs include M923, a biosimilar for autoimmune and inflammatory diseases; M834 for autoimmune and inflammatory diseases; and M511, a monoclonal antibody for oncology. The company's novel products comprise M402, a novel heparan sulfate mimetic that binds to various growth factors, adhesion molecules, and chemokines to inhibit tumor angiogenesis, progression, and metastasis; and the sialylation technology, which is a discovery program that is intended to modify immunoglobulin G antibodies in intravenous immunoglobulin, a drug to treat autoimmune and inflammatory diseases. It has collaboration agreements with Sandoz AG; Baxter International, Inc.; Baxter Healthcare Corporation; and Baxter Healthcare SA. The company was formerly known as Mimeon, Inc. and changed its name to Momenta Pharmaceuticals, Inc. in September 2002. Momenta Pharmaceuticals, Inc. was founded in 2001 and is headquartered in Cambridge, Massachusetts. |
|
| Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
| Shea Richard P | SVP, CFO | May 16 | Sale | 13.31 | 146 | 1,943 | 150,708 | May 20 05:06 PM | | Leicher Bruce | SVP & General Counsel | May 15 | Sale | 13.33 | 269 | 3,586 | 109,980 | May 16 11:50 AM | | WHEELER CRAIG A | President | May 15 | Sale | 13.33 | 1,687 | 22,488 | 338,521 | May 17 04:25 PM | | Bishop John E | Senior VP, Pharmaceutical Scie | May 15 | Sale | 13.33 | 250 | 3,333 | 101,204 | May 17 04:23 PM | | Roach James M. | Senior VP, Development and Chi | May 15 | Sale | 13.33 | 217 | 2,893 | 87,950 | May 17 04:22 PM | | Kaundinya Ganesh Venkataraman | Senior V.P., Research | May 15 | Sale | 13.33 | 217 | 2,893 | 425,852 | May 17 04:19 PM | | Fanucci Marsha | Director | Mar 15 | Sale | 14.15 | 29,400 | 416,010 | 9,000 | Mar 18 01:55 PM | | Stoner Elizabeth | Director | Mar 05 | Sale | 14.00 | 2,040 | 28,560 | 11,143 | Mar 07 11:21 AM | | WHEELER CRAIG A | President | Feb 26 | Sale | 12.58 | 2,109 | 26,531 | 340,208 | Feb 26 03:33 PM | | Roach James M. | Senior VP, Development and Chi | Feb 26 | Sale | 12.58 | 192 | 2,415 | 88,167 | Feb 27 11:08 AM | | Shea Richard P | SVP, CFO | Feb 26 | Sale | 12.58 | 173 | 2,176 | 150,854 | Feb 27 11:04 AM | | Kaundinya Ganesh Venkataraman | Senior V.P., Research | Feb 26 | Sale | 12.58 | 183 | 2,302 | 426,069 | Feb 27 11:01 AM | | Bishop John E | Senior VP, Pharmaceutical Scie | Feb 26 | Sale | 12.58 | 233 | 2,931 | 101,454 | Feb 27 10:55 AM | | Leicher Bruce | SVP & General Counsel | Feb 26 | Sale | 12.58 | 153 | 1,925 | 110,249 | Feb 27 10:54 AM | | Leicher Bruce | SVP & General Counsel | Feb 25 | Sale | 12.43 | 189 | 2,349 | 110,402 | Feb 26 03:35 PM | | WHEELER CRAIG A | President | Feb 25 | Sale | 12.43 | 2,109 | 26,215 | 342,317 | Feb 26 03:33 PM | | Roach James M. | Senior VP, Development and Chi | Feb 25 | Sale | 12.43 | 189 | 2,349 | 88,359 | Feb 27 11:08 AM | | Shea Richard P | SVP, CFO | Feb 25 | Sale | 12.43 | 189 | 2,349 | 151,027 | Feb 27 11:04 AM | | Kaundinya Ganesh Venkataraman | Senior V.P., Research | Feb 25 | Sale | 12.43 | 208 | 2,585 | 426,252 | Feb 27 11:01 AM | | Bishop John E | Senior VP, Pharmaceutical Scie | Feb 25 | Sale | 12.43 | 240 | 2,983 | 101,687 | Feb 27 10:55 AM | | WHEELER CRAIG A | President | Feb 20 | Sale | 12.62 | 2,109 | 26,616 | 344,426 | Feb 21 05:26 PM | | Shea Richard P | SVP, CFO | Feb 20 | Sale | 12.62 | 731 | 9,225 | 151,216 | Feb 21 05:23 PM | | Roach James M. | Senior VP, Development and Chi | Feb 20 | Sale | 12.62 | 188 | 2,373 | 88,548 | Feb 21 05:19 PM | | Bishop John E | Senior VP, Pharmaceutical Scie | Feb 20 | Sale | 12.62 | 239 | 3,016 | 101,927 | Feb 21 05:12 PM | | Leicher Bruce | SVP & General Counsel | Feb 20 | Sale | 12.62 | 188 | 2,373 | 110,591 | Feb 21 04:02 PM | | WHEELER CRAIG A | President | Feb 15 | Sale | 12.16 | 6,750 | 82,080 | 286,535 | Feb 19 03:45 PM | | Roach James M. | Senior VP, Development and Chi | Feb 15 | Sale | 12.26 | 838 | 10,274 | 76,636 | Feb 19 03:41 PM | | Kaundinya Ganesh Venkataraman | Senior V.P., Research | Feb 15 | Sale | 12.26 | 838 | 10,274 | 415,667 | Feb 19 03:36 PM | | Bishop John E | Senior VP, Pharmaceutical Scie | Feb 15 | Sale | 12.26 | 970 | 11,892 | 91,166 | Feb 19 03:34 PM | | Leicher Bruce | SVP & General Counsel | Feb 15 | Sale | 12.26 | 1,040 | 12,750 | 99,779 | Feb 19 01:25 PM | | Kaundinya Ganesh Venkataraman | Senior V.P., Research | Dec 20 | Option Exercise | 0.99 | 7,200 | 7,128 | 416,505 | Dec 21 12:28 PM | | Leicher Bruce | SVP & General Counsel | Nov 27 | Sale | 10.53 | 136 | 1,432 | 100,144 | Nov 27 06:36 PM | | WHEELER CRAIG A | President | Nov 27 | Sale | 10.53 | 2,109 | 22,208 | 293,285 | Nov 28 10:52 AM | | Shea Richard P | SVP, CFO | Nov 27 | Sale | 10.53 | 174 | 1,832 | 140,947 | Nov 28 10:48 AM | | Roach James M. | Senior VP, Development and Chi | Nov 27 | Sale | 10.53 | 192 | 2,022 | 77,474 | Nov 28 10:44 AM | | Kaundinya Ganesh Venkataraman | Senior V.P., Research | Nov 27 | Sale | 10.53 | 183 | 1,927 | 409,305 | Nov 28 10:37 AM | | Bishop John E | Senior VP, Pharmaceutical Scie | Nov 27 | Sale | 10.53 | 233 | 2,453 | 92,136 | Nov 28 10:32 AM | | Leicher Bruce | SVP & General Counsel | Nov 26 | Sale | 10.58 | 188 | 1,989 | 100,280 | Nov 27 06:36 PM | | Shea Richard P | SVP, CFO | Nov 26 | Sale | 10.58 | 188 | 1,989 | 141,121 | Nov 28 10:48 AM | | Roach James M. | Senior VP, Development and Chi | Nov 26 | Sale | 10.58 | 188 | 1,989 | 77,666 | Nov 28 10:44 AM | | Kaundinya Ganesh Venkataraman | Senior V.P., Research | Nov 26 | Sale | 10.58 | 206 | 2,179 | 409,488 | Nov 28 10:37 AM | | Bishop John E | Senior VP, Pharmaceutical Scie | Nov 26 | Sale | 10.58 | 239 | 2,529 | 92,369 | Nov 28 10:32 AM | | WHEELER CRAIG A | President | Nov 26 | Sale | 10.58 | 2,109 | 22,313 | 295,394 | Nov 27 09:56 AM | | Shea Richard P | SVP, CFO | Nov 21 | Sale | 10.74 | 197 | 2,116 | 141,309 | Nov 26 03:51 PM | | WHEELER CRAIG A | President | Nov 20 | Sale | 10.96 | 2,109 | 23,115 | 297,503 | Nov 21 11:22 AM | | Roach James M. | Senior VP, Development and Chi | Nov 20 | Sale | 10.96 | 193 | 2,115 | 77,854 | Nov 21 11:16 AM | | Kaundinya Ganesh Venkataraman | Senior V.P., Research | Nov 20 | Sale | 10.96 | 211 | 2,313 | 409,694 | Nov 21 10:51 AM | | Bishop John E | Senior VP, Pharmaceutical Scie | Nov 20 | Sale | 10.96 | 244 | 2,674 | 92,608 | Nov 21 10:43 AM | | Leicher Bruce | SVP & General Counsel | Nov 20 | Sale | 10.96 | 193 | 2,115 | 100,468 | Nov 21 12:15 PM | | Stoner Elizabeth | Director | Oct 01 | Sale | 14.53 | 1,000 | 14,530 | 9,849 | Oct 02 06:39 PM | | Bishop John E | Senior VP, Pharmaceutical Scie | Aug 29 | Sale | 14.57 | 2,397 | 34,924 | 92,852 | Aug 30 02:05 PM | | Bishop John E | Senior VP, Pharmaceutical Scie | Aug 28 | Sale | 14.35 | 232 | 3,329 | 95,249 | Aug 30 09:57 AM | | WHEELER CRAIG A | President | Aug 28 | Sale | 14.21 | 2,109 | 29,969 | 299,612 | Aug 30 10:17 AM | | Shea Richard P | SVP, CFO | Aug 28 | Sale | 14.35 | 173 | 2,483 | 141,506 | Aug 30 10:10 AM | | Roach James M. | Senior VP, Development and Chi | Aug 28 | Sale | 14.35 | 192 | 2,755 | 78,047 | Aug 30 10:08 AM | | Kaundinya Ganesh Venkataraman | Senior V.P., Research | Aug 28 | Sale | 14.35 | 182 | 2,612 | 409,905 | Aug 30 10:03 AM | | Leicher Bruce | SVP & General Counsel | Aug 28 | Sale | 14.35 | 135 | 1,937 | 100,661 | Aug 29 02:21 PM | | Kaundinya Ganesh Venkataraman | Senior V.P., Research | Aug 23 | Sale | 13.64 | 206 | 2,810 | 410,087 | Aug 27 01:38 PM | | Leicher Bruce | SVP & General Counsel | Aug 23 | Sale | 13.64 | 187 | 2,551 | 100,796 | Aug 27 01:31 PM | | WHEELER CRAIG A | President | Aug 23 | Sale | 13.57 | 2,109 | 28,619 | 301,721 | Aug 27 02:05 PM | | Shea Richard P | SVP, CFO | Aug 23 | Sale | 13.64 | 380 | 5,183 | 141,679 | Aug 27 02:00 PM | | Roach James M. | Senior VP, Development and Chi | Aug 23 | Sale | 13.64 | 187 | 2,551 | 78,239 | Aug 27 01:49 PM | | Bishop John E | Senior VP, Pharmaceutical Scie | Aug 23 | Sale | 13.64 | 238 | 3,246 | 95,481 | Aug 27 01:37 PM | | WHEELER CRAIG A | President | Aug 21 | Sale | 13.63 | 2,109 | 28,746 | 303,830 | Aug 23 08:56 AM | | Roach James M. | Senior VP, Development and Chi | Aug 21 | Sale | 13.78 | 193 | 2,660 | 78,426 | Aug 23 08:54 AM | | Kaundinya Ganesh Venkataraman | Senior V.P., Research | Aug 21 | Sale | 13.78 | 211 | 2,908 | 410,293 | Aug 23 08:50 AM | | Bishop John E | Senior VP, Pharmaceutical Scie | Aug 21 | Sale | 13.78 | 244 | 3,362 | 95,719 | Aug 23 08:49 AM | | Leicher Bruce | SVP & General Counsel | Aug 21 | Sale | 13.78 | 696 | 9,591 | 100,983 | Aug 22 01:19 PM | | Bishop John E | Senior VP, Pharmaceutical Scie | Aug 10 | Sale | 13.58 | 7,485 | 101,646 | 95,963 | Aug 13 04:01 PM | | Stoner Elizabeth | Director | Aug 01 | Sale | 14.21 | 1,010 | 14,352 | 9,182 | Aug 02 03:15 PM | | Shapiro Bennett M | Director | Jul 10 | Sale | 14.12 | 1,600 | 22,592 | 7,000 | Jul 11 05:21 PM | | Shapiro Bennett M | Director | Jun 11 | Sale | 14.84 | 400 | 5,936 | 7,000 | Jun 13 04:01 PM | | Stoner Elizabeth | Director | Jun 04 | Sale | 14.00 | 1,020 | 14,280 | 8,526 | Jun 05 03:46 PM | | WHEELER CRAIG A | President | May 29 | Sale | 13.79 | 2,110 | 29,097 | 331,719 | May 31 10:59 AM | | Bishop John E | Senior VP, Pharmaceutical Scie | May 29 | Sale | 13.93 | 233 | 3,246 | 103,448 | May 31 10:54 AM | | Kaundinya Ganesh Venkataraman | Senior V.P., Research | May 29 | Sale | 13.93 | 182 | 2,535 | 410,504 | May 31 10:48 AM | | Shea Richard P | SVP, CFO | May 29 | Sale | 13.93 | 173 | 2,410 | 95,331 | May 31 10:40 AM | | Roach James M. | Senior VP, Development and Chi | May 29 | Sale | 13.93 | 192 | 2,675 | 78,619 | May 31 10:38 AM | | Leicher Bruce | SVP & General Counsel | May 23 | Sale | 13.90 | 189 | 2,627 | 101,216 | May 25 01:00 PM | | Bishop John E | Senior VP, Pharmaceutical Scie | May 23 | Sale | 13.90 | 240 | 3,336 | 103,681 | May 25 02:12 PM | | Kaundinya Ganesh Venkataraman | Senior V.P., Research | May 23 | Sale | 13.90 | 208 | 2,891 | 410,686 | May 25 02:07 PM | | Roach James M. | Senior VP, Development and Chi | May 23 | Sale | 13.90 | 189 | 2,627 | 78,811 | May 25 02:06 PM | | Shea Richard P | SVP, CFO | May 23 | Sale | 13.90 | 189 | 2,627 | 95,504 | May 25 02:03 PM | | WHEELER CRAIG A | President | May 23 | Sale | 13.98 | 2,109 | 29,484 | 333,829 | May 25 02:02 PM | | Leicher Bruce | SVP & General Counsel | May 22 | Sale | 14.38 | 501 | 7,204 | 101,405 | May 22 06:16 PM |
|
|
|
|
|
|
